pembrolizumab

You have access
Comparison of PD-L1 mRNA Expression Measured with the CheckPoint Typer® Assay with PD-L1 Protein Expression Assessed with Immunohistochemistry in Non-small Cell Lung Cancer
RAMONA ERBER, ROBERT STÖHR, STEFANIE HERLEIN, CLAUDIA GIEDL, RALF JOACHIM RIEKER, FLORIAN FUCHS, JOACHIM H. FICKER, ARNDT HARTMANN, ELKE VELTRUP, RALPH M. WIRTZ and WOLFGANG M. BRUECKL

Anticancer Research December 2017, 37 (12) 6771-6778;
You have access
Adrenal Insufficiency Related to Anti-Programmed Death-1 Therapy
RYO ARIYASU, ATSUSHI HORIIKE, TAKAHIRO YOSHIZAWA, YOSUKE DOTSU, JUNJI KOYAMA, MASAFUMI SAIKI, TOMOAKI SONODA, SHINGO NISHIKAWA, SATORU KITAZONO, NORIKO YANAGITANI and MAKOTO NISHIO

Anticancer Research August 2017, 37 (8) 4229-4232;
You have access
Neoadjuvant Chemoradiotherapy Treatment for a Classic Biphasic Pulmonary Blastoma with High PD-L1 Expression
JOAQUIM BOSCH-BARRERA, FRANCIA HOLGUIN, XAVIER BALDÓ, MATILDE RUBIO, RUT PORTA, RAFAEL FUENTES, CRISTINA TEIXIDÓ, JOSÉ LUIS RAMIREZ, NURIA FERRAN, FERNANDO SEBASTIÁN and RAFAEL ROSELL

Anticancer Research September 2015, 35 (9) 4871-4875;

Main menu